Cargando…

Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]

BACKGROUND: The interest of patients in participating in randomized clinical trials involving treatments has been widely studied, but there has been much less research on interest in preventive trials. The objective of this study was to find out how many women would be interested in a trial involvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hovi, Sirpa-Liisa, Hakama, Matti, Veerus, Piret, Rahu, Mati, Hemminki, Elina
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090584/
https://www.ncbi.nlm.nih.gov/pubmed/15826311
http://dx.doi.org/10.1186/1471-2288-5-12
_version_ 1782123891147145216
author Hovi, Sirpa-Liisa
Hakama, Matti
Veerus, Piret
Rahu, Mati
Hemminki, Elina
author_facet Hovi, Sirpa-Liisa
Hakama, Matti
Veerus, Piret
Rahu, Mati
Hemminki, Elina
author_sort Hovi, Sirpa-Liisa
collection PubMed
description BACKGROUND: The interest of patients in participating in randomized clinical trials involving treatments has been widely studied, but there has been much less research on interest in preventive trials. The objective of this study was to find out how many women would be interested in a trial involving postmenopausal hormone therapy (PHT) and how the women's background characteristics and opinions correlated to their interest. METHODS: The data come from recruitment questionnaires (n = 2000) sent to women in Estonia in 1998. A random sample of women aged 45 to 64 was drawn from the Population Registry. The trial is a two-group randomized trial comparing estrogen-progestogen therapy with placebo or no drugs. A brief description of the study was attached to the questionnaires. Women were not told at this stage of the recruitment which group they would be assigned to, however, they were told of the chance to receive either hormone, placebo or no treatment. RESULTS: After two reminders, 1312 women (66%) responded. Eleven percent of the women approached (17% of the respondents) were interested in joining the trial, and 8% wanted more information before deciding. When the 225 women who stated clearly that they were interested in joining and the 553 women who said they were not interested were compared, it was found that interested women were younger and, adjusting for age, that more had given birth; in other respects, the sociodemographic characteristics and health habits of the interested women were similar to those of the non-interested women. The interested women had made more use of more health services, calcium preparations and PHT, they were more often overweight, and more had chronic diseases and reported symptoms. Interested women's opinions on the menopause were more negative, and they favoured PHT more than the non-interested women. CONCLUSION: Unlike the situation described in previous reports on preventive trials, in this case Estonian women interested in participating in a PHT trial were not healthier than other women. This suggests that trials involving PHT are more similar to treatment trials than to preventive trials. In a randomized controlled trial, more information should be obtained from those women who decline to participate.
format Text
id pubmed-1090584
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10905842005-05-07 Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757] Hovi, Sirpa-Liisa Hakama, Matti Veerus, Piret Rahu, Mati Hemminki, Elina BMC Med Res Methodol Research Article BACKGROUND: The interest of patients in participating in randomized clinical trials involving treatments has been widely studied, but there has been much less research on interest in preventive trials. The objective of this study was to find out how many women would be interested in a trial involving postmenopausal hormone therapy (PHT) and how the women's background characteristics and opinions correlated to their interest. METHODS: The data come from recruitment questionnaires (n = 2000) sent to women in Estonia in 1998. A random sample of women aged 45 to 64 was drawn from the Population Registry. The trial is a two-group randomized trial comparing estrogen-progestogen therapy with placebo or no drugs. A brief description of the study was attached to the questionnaires. Women were not told at this stage of the recruitment which group they would be assigned to, however, they were told of the chance to receive either hormone, placebo or no treatment. RESULTS: After two reminders, 1312 women (66%) responded. Eleven percent of the women approached (17% of the respondents) were interested in joining the trial, and 8% wanted more information before deciding. When the 225 women who stated clearly that they were interested in joining and the 553 women who said they were not interested were compared, it was found that interested women were younger and, adjusting for age, that more had given birth; in other respects, the sociodemographic characteristics and health habits of the interested women were similar to those of the non-interested women. The interested women had made more use of more health services, calcium preparations and PHT, they were more often overweight, and more had chronic diseases and reported symptoms. Interested women's opinions on the menopause were more negative, and they favoured PHT more than the non-interested women. CONCLUSION: Unlike the situation described in previous reports on preventive trials, in this case Estonian women interested in participating in a PHT trial were not healthier than other women. This suggests that trials involving PHT are more similar to treatment trials than to preventive trials. In a randomized controlled trial, more information should be obtained from those women who decline to participate. BioMed Central 2005-04-12 /pmc/articles/PMC1090584/ /pubmed/15826311 http://dx.doi.org/10.1186/1471-2288-5-12 Text en Copyright © 2005 Hovi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hovi, Sirpa-Liisa
Hakama, Matti
Veerus, Piret
Rahu, Mati
Hemminki, Elina
Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]
title Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]
title_full Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]
title_fullStr Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]
title_full_unstemmed Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]
title_short Who wants to join preventive trials? – Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]
title_sort who wants to join preventive trials? – experience from the estonian postmenopausal hormone therapy trial [isrctn35338757]
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090584/
https://www.ncbi.nlm.nih.gov/pubmed/15826311
http://dx.doi.org/10.1186/1471-2288-5-12
work_keys_str_mv AT hovisirpaliisa whowantstojoinpreventivetrialsexperiencefromtheestonianpostmenopausalhormonetherapytrialisrctn35338757
AT hakamamatti whowantstojoinpreventivetrialsexperiencefromtheestonianpostmenopausalhormonetherapytrialisrctn35338757
AT veeruspiret whowantstojoinpreventivetrialsexperiencefromtheestonianpostmenopausalhormonetherapytrialisrctn35338757
AT rahumati whowantstojoinpreventivetrialsexperiencefromtheestonianpostmenopausalhormonetherapytrialisrctn35338757
AT hemminkielina whowantstojoinpreventivetrialsexperiencefromtheestonianpostmenopausalhormonetherapytrialisrctn35338757